



Announcement Summary

Entity name

PHARMAXIS LTD

Announcement Type

New announcement

Date of this announcement

Thursday August 26, 2021

The +securities to be quoted are:

☒ +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
New code to be confirmed	ORDINARY FULLY PAID - NEW	522,000	26/08/2021

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

PHARMAXIS LTD

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ABN

Registration number

75082811630

1.3 ASX issuer code

PXS

1.4 The announcement is

☒ New announcement

1.5 Date of this announcement

26/8/2021



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

☒ +Securities issued under an +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

2.2 The +securities to be quoted are:

☒ Additional +securities in a class that is already quoted on ASX ("existing class")



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class issued under an +employee incentive scheme

FROM (Existing Class)

ASX +security code and description

No security currently exists

FROM (Existing Class)

+Security description

Issue of 522,000 ordinary shares under the Pharmaxis Employee Share Plan.

TO (Existing Class)

ASX +security code and description

PXS : ORDINARY FULLY PAID

Please state the number of +securities issued under the +employee incentive scheme that are not subject to a restriction on transfer or that are to be quoted notwithstanding there is a restriction on transfer

522,000

Please provide details of a URL link for a document lodged with ASX detailing the terms of the +employee incentive scheme or a summary of the terms

Pharmaxis Ltd Employee Share Plan Refer to the summary in the 2021 Annual report available at: <https://www.pharmaxis.com.au/assets/Documents/pdf/02021/ASX/2021-08-12-Pharmaxis-Preliminary-Final-Statement-App-4E-FY21.pdf>

In summary terms, under the Pharmaxis Employee Share Plan, Pharmaxis issues up to \$1,000 of fully paid Pharmaxis ordinary shares to eligible employees of the Group. The CEO and direct reports to the CEO do not participate in this plan. The ordinary shares have the same terms and rank equally with the existing ordinary shares. Subject to certain exceptions, the shares cannot be traded until the earlier of three years after the date of issue or 30 days after the relevant employee ceases to be an employee.

Are any of these +securities being issued to +key management personnel (KMP) or an +associate

☒ No

Issue date

26/8/2021

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

☒ No

If some of the issued +securities do not rank equally:



Is the actual date from which the +securities will rank equally (non-ranking end date) known?

☒ Yes

Provide the actual non-ranking end date

26/8/2024

Please state the extent to which the +securities do not rank equally:

- In relation to the next dividend, distribution or interest payment; or
- For any other reason

The ordinary shares rank equally in all respect with the existing ordinary shares except that the shares cannot be traded until the earlier of three years after the date of issue or 30 days after the relevant employee ceases to be an employee.

Issue details

Number of +securities to be quoted

522,000

Are the +securities being issued for a cash consideration?

☒ No

Please describe the consideration being provided for the +securities

Issue of 522,000 ordinary shares amongst 58 Australian employees of Pharmaxis in accordance with the Pharmaxis Employee Share Plan.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

0.107900

Any other information the entity wishes to provide about the +securities to be quoted

Value of A\$0.1079 per share. Nil consideration being paid by the relevant employees.

**Part 4 - Issued capital following quotation**

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

(A discrepancy in these figures compared to your own may be due to a matter of timing if there is more than one application for quotation/issuance currently with ASX for processing.)

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
PXS : ORDINARY FULLY PAID	453,571,039

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
PXSAG : OPTION EXPIRING 28-JUN-2022 EX NIL PRICE	92,000
PXSAAP : OPTION EXPIRING 06-JUN-2023 EX NIL PRICE	134,750
PXSAAS : PERFORMANCE RIGHTS	18,686,400



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

☒ No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

☒ No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

☒ Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

522,000

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

☒ No